Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy.
about
Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat CancerNoninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects.Nanobody: the "magic bullet" for molecular imaging?Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumorsIn vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies.New radiotracers for imaging of vascular targets in angiogenesis-related diseases.Generation and characterization of a human nanobody against VEGFR-2.The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.PET imaging with ⁸⁹Zr: from radiochemistry to the clinicDevelopment of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS)Coupling Gd‑DTPA with a bispecific, recombinant protein anti‑EGFR‑iRGD complex improves tumor targeting in MRILlama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo.Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.Targeting tetraspanins in cancer.Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target.(89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges.Novel therapy based on camelid nanobodies.Targeting the oncogenic Met receptor by antibodies and gene therapy.Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.Nanobody-based cancer therapy of solid tumors.Radiolabelled Polymeric Materials for Imaging and Treatment of Cancer: Quo Vadis?Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.In vivo near-infrared fluorescence targeting of T cells: comparison of nanobodies and conventional monoclonal antibodies.Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.Alternative reagents to antibodies in imaging applications.Histidine-rich stabilized polyplexes for cMet-directed tumor-targeted gene transfer.Escherichia coli surface display for the selection of nanobodies.Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.Single Domain Antibodies as New Biomarker Detectors.Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.Screening and antitumor effect of an anti‑CTLA‑4 nanobody.89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection.Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment.
P2860
Q26739702-9345F7CE-96CC-46E9-BE28-8DC1E684F78AQ26822871-CCA03CBD-ABF5-4235-B6CC-35BC1EE791A3Q30442626-3909CF92-D777-4FB5-AF66-FB4A6930E950Q33753135-BBCDF310-6A18-43F8-AEC0-6BC3B6F138B2Q33819576-02E644AD-D897-48E7-B9F1-186D44F38804Q34216877-517501C7-3ED7-4DA8-A667-0B98A3E85DBCQ34523277-CB5D3108-0FCD-4ECA-9533-83C6F25F3E96Q35740444-7ED1FAFA-1304-48A4-B3BC-8DD897227B03Q36454584-63AC6B50-9F0F-4CB6-8501-85CA12F2DCEDQ36841541-55849593-4D12-44FC-AA22-D8677EEBC714Q36915069-72DCC84F-C78A-4C2F-BE00-4A586B384A04Q37226145-C155376A-E546-4341-A4A1-482E51DBD891Q37236103-D83CFFBA-1004-40F1-98E8-BCADD5D32688Q38033584-553ED7B2-540F-4E63-B797-9DD57BF5469DQ38106992-00BB000D-B673-42C9-AA33-2DD15CDFE7DEQ38111973-2082672C-55B2-4CC6-B1A5-84EB58DB6AC7Q38151739-70E7C2B9-2DF0-44E7-96D8-561B7891B356Q38216590-A73B6224-0A16-48C5-AB03-28C4167B0343Q38230884-317B8D62-4FF4-4CA8-9BAF-1A850274A61FQ38322471-0C47EEE1-C990-47B2-A8B9-C5B4C6A5AF17Q38755295-CF60564F-A03E-4508-AB56-25413A5D760DQ38931192-86489BC0-CB08-4411-B1BA-EB302989C31EQ39024388-C7936BB1-56C5-45D3-8AD8-0223C91405EFQ39109310-3BF65CB1-313B-47B4-BAA9-5E12E088C9D5Q41579389-62904409-BA3E-4368-A77E-87F115411F3AQ42159274-C1F324D1-4BA6-42F2-839A-900B92AB7847Q42770832-2F55E10F-DDCD-4F9C-9966-7746FB3C6BDAQ47099672-95FCAAF0-8C46-4345-9A79-6FC0DBE12314Q47099886-7D694A88-65B4-458A-AF06-4B7D1FCBD024Q47134203-F6D3187A-3B66-4610-831E-43D51853C39CQ47365479-95963EEF-002E-4A8D-B519-9DAA1BA5F8C6Q48270323-CDD8C44E-3C30-4801-A471-6F436B551DFEQ52362264-3C57C9D8-DC17-49D8-AAE4-93B82DC9B96B
P2860
Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Nanobodies targeting the hepat ...... for molecular cancer therapy.
@en
Nanobodies targeting the hepat ...... for molecular cancer therapy.
@nl
type
label
Nanobodies targeting the hepat ...... for molecular cancer therapy.
@en
Nanobodies targeting the hepat ...... for molecular cancer therapy.
@nl
prefLabel
Nanobodies targeting the hepat ...... for molecular cancer therapy.
@en
Nanobodies targeting the hepat ...... for molecular cancer therapy.
@nl
P2093
P1476
Nanobodies targeting the hepat ...... for molecular cancer therapy.
@en
P2093
Guus A M S van Dongen
Hilde Revets
Jo Vercammen
Joost A Kolkman
Maria J W D Vosjan
Marijke Stigter-van Walsum
P304
P356
10.1158/1535-7163.MCT-11-0891
P577
2012-02-07T00:00:00Z